Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Hannah Kinvig"'
Autor:
Hannah Kinvig, Rajith K. R. Rajoli, Henry Pertinez, Lalitkumar K. Vora, Fabiana Volpe-Zanutto, Ryan F. Donnelly, Steve Rannard, Charles Flexner, Marco Siccardi, Andrew Owen
Publikováno v:
Pharmaceutics, Vol 15, Iss 12, p 2709 (2023)
Microarray patches (MAPs) are currently under investigation as a self-administered, pain-free alternative used to achieve long-acting (LA) drug delivery. Cabotegravir is a potent antiretroviral that has demonstrated superior results over current pre-
Externí odkaz:
https://doaj.org/article/886b6f7e85414543af1debf92373d739
Autor:
Maiara Camotti Montanha, Nicolas Cottura, Michael Booth, Daryl Hodge, Fazila Bunglawala, Hannah Kinvig, Sandra Grañana-Castillo, Andrew Lloyd, Saye Khoo, Marco Siccardi
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
The aim of the study was to apply Physiologically-Based Pharmacokinetic (PBPK) modelling to predict the effect of liver disease (LD) on the pharmacokinetics (PK) of dexamethasone (DEX) in the treatment of COVID-19. A whole-body PBPK model was created
Externí odkaz:
https://doaj.org/article/32eb66361be14f55b60c46c7d5117e7c
Autor:
Yesenia L. Franco, Lais Da Silva, Nitin Charbe, Hannah Kinvig, Soyoung Kim, Rodrigo Cristofoletti
Publikováno v:
Pharmaceutical Research. 40:405-418
Publikováno v:
The Journal of Clinical Pharmacology. 62:835-846
Despite the advancement of antiretroviral therapy (ART) for the treatment of human immunodeficiency virus (HIV), drug-drug interactions (DDIs) remain a relevant clinical issue for people living with HIV receiving ART. Antiretroviral (ARV) drugs can b
Autor:
Fazila Bunglawala, Daryl Hodge, Sandra Grañana-Castillo, Saye Khoo, Michael Booth, Andrew Lloyd, Marco Siccardi, Nicolas Cottura, Maiara Camotti Montanha, Hannah Kinvig
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
The aim of the study was to apply Physiologically-Based Pharmacokinetic (PBPK) modelling to predict the effect of liver disease (LD) on the pharmacokinetics (PK) of dexamethasone (DEX) in the treatment of COVID-19. A whole-body PBPK model was created
Autor:
Nicolas Cottura, Maiara Camotti Montanha, Hannah Kinvig, Catriona Waitt, Alice Howarth, Paolo Denti, Marco Siccardi, Fazila Bunglawala, Andrew Lloyd, Francesc Fabrega
Publikováno v:
CLINICAL PHARMACOKINETICS
ObjectivesThe aim of this study was to simulate the drug-drug interaction (DDI) between ritonavir-boosted atazanavir (ATV/r) and rifampicin (RIF) using physiologically based pharmacokinetic (PBPK) modelling, and to predict suitable dose adjustments f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94fea0b2fbf787aaa5ef6d1a5a8cc8cd
Autor:
Maiara Camotti Montanha, Francesc Fabrega, Alice Howarth, Nicolas Cottura, Hannah Kinvig, Fazila Bunglawala, Andrew Lloyd, Paolo Denti, Catriona Waitt, Marco Siccardi
Publikováno v:
Clinical Pharmacokinetics. 61:1641-1641
Autor:
Felix Stader, Hannah Kinvig, Catia Marzolini, Marco Siccardi, Manuel Battegay, Melissa A. Penny
Publikováno v:
CLINICAL PHARMACOKINETICS
Medication use is highly prevalent with advanced age, but clinical studies are rarely conducted in the elderly, leading to limited knowledge regarding age-related pharmacokinetic changes. The objective of this study was to investigate which pharmacok
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06eb41c648a6f01c47a1e7654a871872
Autor:
Hannah Kinvig, Catia Marzolini, Marco Siccardi, Felix Stader, Manuel Battegay, Melissa A. Penny
Publikováno v:
CLINICAL PHARMACOKINETICS
Aging is characterized by anatomical, physiological, and biological changes that can impact drug kinetics. The elderly are often excluded from clinical trials and knowledge about drug kinetics and drug-drug interaction magnitudes is sparse. Physiolog
Autor:
Saye Khoo, Hannah Kinvig, Felix Stader, Andrew Owen, Catia Marzolini, Manuel Battegay, Marco Siccardi
Publikováno v:
Antimicrobial Agents and Chemotherapy
Despite their high potential for drug-drug interactions (DDI), clinical DDI studies of antiretroviral drugs (ARVs) are often lacking, because the full range of potential interactions cannot feasibly or pragmatically be studied, with some high-risk DD